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Heparanase is an endo-b(1–4)-D-glucuronidase that degrades
heparan sulfate (HS) polysaccharide side chains. The role of
heparanase in metastasis, angiogenesis, and inflammation
has been established. Recent data suggest a role for
heparanase in several proteinuric diseases and an increased
glomerular heparanase expression is associated with loss of
HS in the glomerular basement membrane (GBM).
Furthermore, an increase in heparanase activity was detected
in urine from proteinuric patients. Mice with transgenic
heparanase overexpression developed mild proteinuria.
Glomerular heparanase activity is proposed to lead to loss of
HS in the GBM and proteinuria. Because the primary role of
GBM HS for charge-selective permeability has been
questioned recently, heparanase may induce or enhance
proteinuria by (i) changes in the glomerular cell–GBM
interactions, due to loss of HS; (ii) release of HS-bound factors
and HS fragments in glomeruli; or (iii) intracellular signaling
by binding of heparanase to glomerular cells. Which of these
mechanisms is prevailing requires further research. The
precise mechanisms leading to increased heparanase
expression in the different glomerular cell types remain
elusive, but may involve hyperglycemia, angiotensin II,
aldosterone, and reactive oxygen species. This review focuses
on the role of heparanase in HS degradation in proteinuric
diseases and the possibility/feasibility of heparanase
inhibitors, such as heparin(oids), as treatment options.
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HEPARAN SULFATE PROTEOGLYCANS
Heparan sulfate (HS) proteoglycans (HSPGs) are widely
distributed glycoproteins with many ascribed biological and
structural functions. HSPGs consist of a core protein, to
which linear HS polysaccharide chains are covalently linked.
HSPGs are present in extracellular matrices, especially
basement membranes, and on cell surfaces where they are
involved in cell–cell and cell–matrix adhesion. HSPGs
function in storage and release of ligands including extra-
cellular matrix molecules, enzymes, enzyme inhibitors,
growth factors, chemokines, and cytokines, which are
involved in physiological and pathological processes such as
tissue repair, embryogenesis, inflammation, autoimmunity,
angiogenesis, and tumor metastasis.1 The role of HS in
glomerular inflammation was recently reviewed in this
journal by Rops et al.2 The specific interactions between
HS and its ligands largely depend on the N- and O-sulfation
pattern of HS and the presence of specific carboxyl groups.
HS chain biosynthesis occurs in the Golgi apparatus and
involves more than 15 different enzymes. The HS chain
consists of up to 300 repeating N-acetyl-glucosamine and
glucuronic acid residues, which can be modified at various
positions. The first HS modification is N-deacetylation and
subsequent N-sulfation of N-acetyl-glucosamine to GlcNS
residues, which is catalyzed by four N-deacetylase/N-
sulfotransferase isoenzymes. A single glucuronosyl C5-
epimerase catalyzes the epimerization of glucuronic acid to
iduronic acid. Finally, a large family of 2-O-, 3-O-, and 6-O-
sulfotransferase isoenzymes catalyzes the 2-O-, 3-O-, and
6-O-sulfation. The large number of possible combinations/
modifications in the HS chain leads to an enormous
structural and functional diversity of HS. In glomeruli, HS
is attached to different core proteins depending on their
location. Extracellular matrix core proteins include agrin,
perlecan, and collagen XVIII, whereas glomerular cell-
associated core proteins include syndecans and glypicans.1,2
Agrin is the most abundantly expressed core protein in the
glomerular basement membrane (GBM).3
HS ALTERATIONS IN PROTEINURIC DISEASES
Until recently, the covalently linked HS chains of agrin were
considered to be the major determinants for the charge-
dependent permeability of the GBM. This was supported by a
number of observations including an increased GBM
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permeability for negatively charged molecules (i.e., albumin)
after GBM HS removal by bacterial heparitinase.4 Previously,
we have developed several antibodies specific for the HSPG
core protein agrin and its HS side chains.5,6 In rats, selective
proteinuria developed when a monoclonal antibody (i.e.,
JM403) directed against HS in the GBM was injected
intravenously.7 Moreover, we consistently demonstrated a
decrease of GBM HS in proteinuric diseases, including overt
diabetic nephropathy, systemic lupus erythematosus, mini-
mal change, and membranous glomerulopathy, whereas the
amount of the core protein agrin remained unaltered.6
Diabetic nephropathy in humans is characterized by micro-
albuminuria which is, at later stages, associated with a loss of
the negative charge of the GBM.6,8 Interestingly, administra-
tion of heparin(oids) in experimental and human diabetic
nephropathy prevented loss of GBM anionic sites and was
associated with decreased albuminuria.9–11 The underlying
protective mechanism(s) of this observation remain elusive
and will be further discussed below.
Whether HS in the GBM is primarily responsible for the
charge-dependent filtration has recently become question-
able. Firstly, recent data in early human and experimental
diabetic nephropathy revealed an increase in albumin
excretion without structural changes in glomerular HS
expression.12 No albuminuria developed after in vivo
degradation of HS in the GBM by heparitinase I in rats.13
Recent studies revealed that podocyte-specific agrin knockout
mice (which do not express HS in the GBM) also do not
develop proteinuria (Harvey et al. Podocyte-derived agrin is
responsible for glomerular basement membrane anionic
charge [Abstract]. J Am Soc Nephrol 2005; 16: 1A) and mice
with transgenic heparanase overexpression (almost comple-
tely lacking HS in the GBM) surprisingly only develop mild
albuminuria.14 In addition, proteinuria in podocyte-specific
EXT-1 knockout mice, lacking the key enzyme glycosyltrans-
ferase responsible for HS polymerization, was only detected
after 8 months (Chen S, Holzman L, Yamaguchi Y et al.
Elimination of heparan sulfate glycosaminoglycans (HS-
GAGs) from the glomerular basement membrane (GBM)
using Cre-Lox technology has profound effect on podocyte
ultrastructure and function [Abstract]. J Am Soc Nephrol
2006; 17: 25A).
It remains to be determined whether these observations
can be extrapolated directly to glomerular diseases. In the
heparitinase-induced loss of HS, the observation period was
only 24–48 h and a bacterial HS-degrading enzyme was
applied.13 In the models with a targeted disruption leading to
HS loss, as described above, compensatory and adaptive
mechanisms were not formally excluded, although in the
agrin knockout mice, the net negative charge of the GBM was
decreased. Furthermore, a gradual decrease of HS may induce
pathogenic mechanisms, which are different from those in
acutely induced loss of HS or genetic manipulation that
prevents HS expression in the GBM. Remarkably, a decrease
of HS in the GBM, which inversely correlated with
proteinuria, has been consistently documented in the
majority of glomerular diseases,6,8 which in some cases was
associated with the upregulation of the HS-degrading
enzyme, heparanase.
HEPARANASE
The gene encoding heparanase (HPSE-1) is expressed in
several cell types and tissues, and is abundantly expressed in
lymphoma, melanoma, and carcinoma cells.15,16 Heparanase
is an endo-b(1–4)-D-glucuronidase that cleaves the glycosidic
bond within the HS chain via hydrolysis. The active site of
heparanase may involve residues Glu225 and Glu343 that
participate in the cleavage of HS.17 HS cleavage by
heparanase yields HS fragments 5–7 kDa in size (10–20 sugar
units) and the proposed cleavage site for heparanase requires
N- and 6-O-sulfated moieties in a specific orientation
(Figure 1).18,19
SYNTHESIS AND CELLULAR TRAFFICKING OF HEPARANASE
The heparanase gene encodes for a 543 amino-acid polypep-
tide, giving rise to a 68 kDa, pre-proheparanase containing a
signal peptide sequence (residues 1–35). The latent
pre-proheparanase is processed in the endoplasmatic reticu-
lum where it is glycosylated and the signal peptide is cleaved
off, yielding the latent 65 kDa proheparanase. Thereafter, it is
transported to the Golgi apparatus, packaged into vesicles
and secreted. The secreted enzyme is then re-internalized
through binding to cell-associated HSPG (in particular
syndecan), low-density lipoprotein receptor-related protein,
mannose 6-phosphate receptors, and possibly other recep-
tors.20 The internalized 65 kDa protein is then transferred to
late endosomes/lysosomes, where it is proteolytically pro-
cessed by cathepsin L21 into the active heterodimer, which
consists of an 8 kDa N-terminal subunit and a 50 kDa
C-terminal subunit (Figure 2).
REGULATION OF HEPARANASE ACTIVITY
Heparanase activity must be tightly regulated to ensure
structural integrity of basement membranes and coordinated
growth factor release. Moreover, its regulation is cell-type
specific. Basal heparanase mRNA expression is positively
regulated by the transcription factors Ets1, Ets2, Sp1, and
GA-binding protein, whereas heparanase gene expression is
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Figure 1 | Heparanase cleavage site and HS substrate specificity.
The minimal oligosaccharide sequence in HS that is necessary for
substrate recognition by heparanase is suggested to be a highly
sulfated trisaccharide GlcN-GlcUA-GlcN. Furthermore, at least one
N-sulfate group on the reducing side of glucosamine and a
6-O-sulfate group on the nonreducing side of glucosamine, are
considered to be crucial for substrate recognition.18,19
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downregulated by heparanase promoter methylation.22 In
addition, post-translational regulation may occur at several
processing sites including the endoplasmatic reticulum, Golgi
apparatus, and cell membrane (where secretion, internaliza-
tion, and processing into the active form occurs). The
optimal pH for heparanase enzyme activity is between pH 5.0
and 6.0. At neutral pH, heparanase is able to bind HS,
however, no enzymatic activity is detectable.16 Hence,
heparanase enzymatic activity is limited to acidic micro-
environments, for example at inflammatory sites, tumor
cores, and at the GBM facing sites of podocytes, whereas at
physiological pH, heparanase functions as a cell adhesion and
signaling molecule.23 Finally, naturally occurring heparanase
inhibitors, such as heparin or HS degradation products,
appear to affect heparanase activity and/or binding.
INVOLVEMENT OF HEPARANASE IN PHYSIOLOGICAL AND
PATHOLOGICAL PROCESSES
Heparanase is involved in many biological and pathological
processes.22 Activated immune cells, including T cells and
macrophages, express active heparanase, which upon libera-
tion facilitates diapedesis by cleavage of HS in the
extracellular matrix and basement membranes. Cell homing
to sites of inflammation can be arrested by heparanase
inhibition. Moreover, degradation of HS by heparanase
releases HS-bound factors (including fibroblast growth
factor, vascular endothelial growth factor, connective tissue
growth factor, and chemokines), thereby potentially enhan-
cing pathological processes such as tumor growth, and
enhancing angiogenesis and immune reactions. Many
investigators have studied the importance of heparanase in
tumor cell biology. Briefly, tumor cell invasiveness is
correlated with heparanase expression and activity. Further-
more, heparanase inhibition arrests metastatic disease
progression. Enhanced heparanase expression correlates with
metastatic potential, tumor vascularity, and reduced post-
operative survival of cancer patients.22 Human microvascular
endothelial cells also express heparanase, which can be
upregulated upon activation with proinflammatory cytokines
or fatty acids, whereas heparanase expression can be down-
regulated after stimulation with vascular endothelial growth
factor.24 Similarly, we have recently found that conditionally
immortalized mouse glomerular endothelial cells express
heparanase, which can be upregulated by proinflammatory
cytokines.25
HEPARANASE EXPRESSION IN PROTEINURIC DISEASES
Published studies revealed enhanced glomerular heparanase
expression in several experimental and human glomerular
diseases (Table 1). The fact that heparanase is able to cleave
HS in the GBM, suggests that heparanase expression may be
responsible for the decrease of HS in the GBM. The first
observation that the active form of heparanase may play a
role in the development of proteinuria was made in rats with
puromycin aminonucleoside-induced nephrosis at day 14
Pre-proheparanase:
68 kDa
Proheparanase:
Active heparanase
8 kDa+50 kDa
Heterodimer
+
65 kDa
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Figure 2 | Heparanase processing. Top: heparanase is synthesized as
a latent pre-proheparanase of 68 kDa, which is targeted to the
endoplasmatic reticulum by a signal peptide (s.p., Met1–Ala35).
Middle: after cleavage of the s.p., the 65 kDa inactive proheparanase
is transported to the Golgi and secreted, processes that depend on
glycosylation. Six putative glycosylation sites ( ) are indicated.
Bottom: heparanase is processed into the active enzyme after
removal of a linker domain (Ser110–Glu157) by cathepsin L, yielding an
active heterodimer composed of 8 kDa (Gln34–Glu109) and 50 kDa
(Lys158–Ile543) subunits. Glu225 and Glu343, located in the active site of
the enzyme are critical for heparanase enzymatic activity.
Table 1 | Involvement of HS and heparanase expression in proteinuric diseases
Disease Species HS in GBM Glomerular heparanase expression Reference
Streptozotocin-induced DNP Rat Reduced (n.s.) Increased 14
Mouse Reduced (n.s.) Increased 14
Adriamycin nephropathy Rat Reduced Increased 32
PHN Rat Reduced Increased 28, 29
PAN nephrosis Rat n.a. Increased 26
Anti-GBM nephritis Mouse n.a. Increased 38
Lupus Mouse Masked by immune complexes Unaltered 25
DNP Human Reduced Increased 14, 34, 35
MCD Human Reduced Increased Rutjes et al.*
MG Human Reduced Increased Rutjes et al.*
IgA nephropathy Human Reduced Increased Rutjes et al.*
SLE Human Masked by immune complexes Unaltered 25
DNP, diabetic nephropathy; GBM, glomerular basement membrane; HS, heparan sulfate; MCD, minimal change disease; MG, membranous glomerulopathy; n.a., not analyzed
in this study; n.s., not significant; PAN nephrosis, puromycin aminonucleoside-induced nephrosis; PHN, passive Heymann nephritis; SLE, systemic lupus erythematosus.
*Rutjes et al. Published abstract: The role of heparanase in the pathophysiology of idiopathic nephrotic syndrome. Nephrology 2005; 10(Suppl): A117–A232.
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(this model is analogous to minimal change disease in
humans).26 Interestingly, at day 5 of the disease, an increased
amount of the inactive form of heparanase was expressed,
suggesting that increased heparanase activity was probably
not involved in the initiation of proteinuria. Heparanase
expression in puromycin aminonucleoside nephrosis was
mainly localized in podocytes. In passive Heymann nephritis,
a rat model for membranous glomerulopathy in which a
decrease of HS in the GBM has been observed,27 glomerular
heparanase expression was increased threefold in the
proteinuric phase.28 Heparanase expression was mainly
confined to endothelial cells and podocytes. Urine from
proteinuric rats had a fourfold higher amount of heparanase
activity, compared to control nonproteinuric animals.
Complement activation was required for induction of both
proteinuria and heparanase expression in passive Heymann
nephritis. Treatment with a polyclonal anti-heparanase
antibody resulted in a threefold reduction of proteinuria,
suggesting that heparanase activity contributed to the
development of proteinuria. Because passive Heymann
nephritis and puromycin aminonucleoside nephrosis are
both characterized by podocyte changes, activation of
podocytes could be one of the potential mechanisms that
leads to glomerular heparanase expression and activity.
Inhibition of heparanase with PI-88, a highly sulfated
oligosaccharide, in experimental passive Heymann nephritis
reduced proteinuria by twofold in the absence of an immune
modulating effect, whereas the amount of HS in the GBM
was preserved.29 Unexpectedly, transgenic overexpression of
human heparanase in mice resulted in slightly elevated levels
of proteinuria, whereas expression of HS in the GBM, almost
completely disappeared.14,30 In rats with adriamycin nephro-
pathy, a decrease of HS in the GBM was observed, which
could be reversed after treatment with an ACE inhibitor.31
Very recently, we showed that the decrease in glomerular HS
in this model was associated with an increase in glomerular
heparanase expression. Treatment with an angiotensin II
receptor antagonist reduced the increased heparanase ex-
pression and proteinuria, and restored the expression of HS
in the GBM.32 Furthermore, reactive oxygen species,
especially hydroxyl radicals, are known to be involved in
the development of proteinuria in adriamycin nephropathy
by direct depolymerization of HS.33 Scavenging of hydroxyl
radicals by dimethylthiourea prevented both the decrease in
HS and the increase in glomerular heparanase expression.32
In rodent models of streptozotocin-induced diabetic nephro-
pathy, we also found an inverse correlation between
heparanase mRNA/protein and HS expression.14
Recently, Maxhimer et al.34 showed increased glomerular
heparanase expression in patients with diabetes and found
that in vitro expression of heparanase in cultured podocytes
was upregulated by hyperglycemia. Furthermore, we recently
showed that a decreased expression of HS in the GBM was
associated with an increased glomerular heparanase expres-
sion in patients with overt diabetic nephropathy, as shown in
Figure 3.14 Heparanase expression was also upregulated in
glomeruli of patients with minimal change disease, membra-
nous glomerulopathy, and IgA nephropathy (Rutjes et al. The
role of heparanase in the pathophysiology of idiopathic
nephrotic syndrome [Abstract]. Nephrology 2005; 10 (Suppl):
A117–A232). Interestingly, an increased expression of hepar-
anase was also detected in the cytoplasm of proximal tubules
in diabetic patients, whereas heparanase was also observed
constitutively in tubuli of controls, suggesting a role for
heparanase in normal tubular physiology.
Urinary heparanase activity has been detected in some
patients with type 1 diabetes who were either normoalbu-
minuric or microalbuminuric, whereas it was undetectable in
control urine samples.35 A newly developed enzyme-linked
immunosorbent assay method also detected heparanase in
the urine of diabetic and cancer patients.36 Because
heparanase expression is also increased in tubuli from
patients with diabetes, it is conceivable that the observed
increase in heparanase activity in the urine of these patients
originates from tubular cells, rather than from podocytes or
glomerular endothelial cells. An increased urinary heparanase
activity is not restricted to diabetic nephropathy, because it
was also detected in patients with minimal change disease,
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Figure 3 | Heparanase and HS expression in diabetic nephropathy. (a) A normal linear staining of HS and agrin along the capillary wall
was detected in controls, whereas in patients with overt diabetic nephropathy, a loss of HS in the GBM and normal agrin expression were
observed. (b) The reduction of HS in the GBM of patients with overt diabetic nephropathy was associated with an increase in glomerular
heparanase expression. In controls, no detectable glomerular heparanase expression was observed.14
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membranous glomerulopathy, and focal segmental glomer-
ulosclerosis (Holt et al.37 and Rutjes et al. The role of
heparanase in the pathophysiology of idiopathic nephrotic
syndrome [Abstract]. Nephrology 2005; 10 (Suppl):
A117–A232).
Because the primary role of HS in the charge-selective
properties of the GBM is questioned recently, as discussed
above, the increase of heparanase expression and the decrease
of HS in the GBM in glomerular diseases could be a
consequence rather than a cause of proteinuria. Indeed,
interventions (inhibition of the renin-angiotensin-aldoster-
one system, reactive oxygen species scavenging) leading to a
reduction of proteinuria also induced a regression of
heparanase expression.32 However, there is evidence against
proteinuria-induced heparanase expression and loss of HS. In
the studies of Leviodiotis et al.,28,29,38 in which heparanase
activity was neutralized with either anti-heparanase anti-
bodies or the heparanase inhibitor PI-88, proteinuria was
reduced. In addition, not in all proteinuric diseases, such as
lupus nephritis,25 an increase in glomerular heparanase
expression was found. Also in overload nephropathy
proteinuria was not associated with upregulation of hepar-
anase.32 Despite the recent observations that question the
primary role of HS in charge-selective filtration, in our
opinion, there could still be a role of heparanase and
heparanase-mediated loss of HS in the development of
proteinuria. Firstly, heparanase can disturb cell–GBM inter-
actions by the degradation of HS. This could lead to the loss
of podocytes in the urine, which has been described for
various glomerular diseases.39 Glomerular cells with a
disturbed cell–GBM interaction due to loss of HS may
respond different to (pathogenic) signals than in the normal
situation. Secondly, heparanase activity may lead to the
release of HS-bound factors (growth factors, cytokines,
chemokines) and bioactive HS fragments, thereby modulat-
ing cellular processes in glomerular cells involved in the
development of proteinuria. Finally, active or inactive
heparanase is also capable of binding to HSPG and other
receptors, thereby inducing signaling cascades, which may be
involved in the development or enhancement of proteinuria.
A scheme describing the postulated heparanase-mediated
mechanisms that could be involved in the development of
proteinuria is presented in Figure 4.
INTERVENTION BY HEPARIN(OIDS) IN PROTEINURIC
DISEASES
Because heparanase is involved in tumor metastasis, angio-
genesis, and inflammation, and may be involved in the
development or enhancement of proteinuria in various
glomerular diseases, heparanase is an attractive target for
the development of novel inhibitors. Several inhibitory
molecules have been developed, such as neutralizing anti-
heparanase antibodies, peptides, modified heparin fragments,
and several other polyanionic molecules such as PI-88, and
laminaran sulfate.40 PI-88 is currently undergoing phase II/III
clinical trials for several types of cancer. Non-anticoagulant
N-acetylated, glycol-split heparins efficiently and specifically
inhibit heparanase activity, but have a half-life shorter than
unfractionated heparin.41 The most recently isolated or
developed heparanase inhibitors were reviewed by Ferro
et al.40 Although heparin and heparin derivatives have many
biological activities,42 some of these compounds inhibit
heparanase activity effectively.40 In face of the renoprotective
effects of heparin(oids) in diabetic nephropathy,9 it is
tempting to speculate that heparanase inhibition may
contribute to this beneficial effect.
FUTURE PERSPECTIVES
The detection of increased expression of heparanase in
glomerular diseases has become evident over the last 5 years.
Currently, studies are in progress, aiming to unravel how
heparanase expression and activity are regulated in podocytes
and glomerular endothelial cells. Hyperglycemia,34 angioten-
sin II, reactive oxygen species,32 and aldosterone (preliminary
data) have been shown to regulate heparanase expression/
activity in podocytes. The importance of heparanase will be
further evaluated using (podocyte-specific) heparanase
knockout mice. Induction of proteinuric diseases in this
knockout model or in the transgenic heparanase over-
expressing mouse model, including diabetic nephropathy,
may provide further clues as to the exact role of heparanase
and the loss of HS in the development of proteinuria. Specific
inhibitors of heparanase activity need to be developed to
establish the importance of heparanase in the development of
proteinuria and glomerular diseases. Heparin derivatives
2
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Figure 4 | Postulated mechanisms for development of proteinuria
by heparanase-induced HS degradation. Mechanisms that could
lead to the development of proteinuria are as follows: (1) HS ( ) in
the GBM and/or on the cell surface of podocytes and glomerular
endothelial cells, can be cleaved off by active ( ) heparanase, which
may disturb the glomerular cell–GBM interactions; (2) cleavage of HS
may result in release of several HS-bound factors such as growth
factors, cytokines and chemokines ( ), and bioactive HS fragments,
which may enhance glomerular damage and thereby proteinuria and;
(3) active and inactive ( ) heparanase may bind to cell surface HSPG,
other receptors ( ) or may function as adhesion molecule itself,
which may induce a signaling cascade ( ) that results in a change of
cell properties. Potentially, all these mechanisms may result in
detachment of podocytes or flattening of podocyte foot processes
and the development of proteinuria. Mechanisms depicted for the
apical surface of podocytes may also act on the basal sites of
podocytes and/or the glomerular endothelial cells. N, nucleus.
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could constitute such inhibitors, if the heparanase inhibitory
capacity can be separated from the anticoagulant activity. To
evaluate the relative significance of heparanase, it is
important to select those fractions that have a maximal
heparanase inhibitory effect and minimal anticoagulant
activity. Other potential target sites may be at the level of
heparanase transcription, trafficking, and processing.
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